论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
同时放化疗联合抗 PD-1 治疗 HER2 阴性晚期胃腺癌持久反应:一个病例报告
Authors Yu S, Cai L, Lin F, Wu X, Zhang C, Liu X, Li W
Received 1 July 2019
Accepted for publication 3 September 2019
Published 19 September 2019 Volume 2019:12 Pages 7691—7698
DOI https://doi.org/10.2147/OTT.S221436
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Shashank Kaushik (PT)
Peer reviewer comments 2
Editor who approved publication: Dr Sanjeev Srivastava
Abstract: Advanced gastric cancer (AGC) is difficult to treat with poor prognosis. Despite various possible treatments, the median survival time of such patients remains unsatisfactory. Therefore, new therapeutic approaches or combinations need to be further explored. We herein reported a case of a 54-year-old male patient who was initially diagnosed with HER2-negative advanced gastric cancer. Based on previous studies and patient’s desire, we made a therapeutic plan: the combination of concurrent radiochemotherapy and immune checkpoint blockade therapy. After about 4 months of combined therapy, the patient showed satisfactory complete response to tumor lesions even metastatic lesions (CR, disappearance of all target lesions). In summary, the combination of concurrent SOX regimen chemotherapy, stomach radiotherapy and PD-1 antibody immunotherapy is effective in the treatment of advanced gastric cancer.
Keywords: PD-1 antibody immunotherapy, radiotherapy, advanced gastric cancer, SOX regimen chemotherapy, concurrent therapy
